This webinar, hosted by Patrick Short, CEO of Sano Genetics, and featuring Dr. Mark Kotter, CEO of bit.bio, focused on precision medicine in multiple sclerosis....
Continue reading
Decentralized and hybrid clinical trials hold significant promise for improving access and reducing patient burden. But implementing them introduces operational...
Continue reading
In this webinar, Patrick Short (Co-Founder and CEO at Sano Genetics) and Will Jones (Co-Founder and CTO at Sano Genetics) discuss the technical challenges of bi...
Continue reading
If you missed our webinar, you can catch up on an exciting discussion about the future of precision medicine research in multiple sclerosis here on our blog.
Continue reading
Genetic testing has expanded significantly, both in clinical contexts and beyond. Understanding the distinctions between testing modalities—genotyping, targeted...
Continue reading
Advances in large-scale genome sequencing, data storage, and analysis are accelerating the development of precision medicine across a growing number of therapeu...
Continue reading
Polygenic risk scores enable clinicians and researchers to stratify patient populations by genetic risk, informing decisions on screening schedules, therapeutic...
Continue reading